BIO · Bio-Rad Laboratories, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 4, 2026TL;DR. Bio-Rad reported Q2 revenue essentially flat at $651M but down 1.9% currency-neutral, with life science down 5.1% currency-neutral and non-GAAP operating margin contracting to 12.5% from 13.6%, while reaffirming full-year guidance and announcing a new restructuring targeting $30–$35M in net annualized savings by end of 2027.
- + Scylla acquisition's first anniversary is delivering margin performance ahead of original expectations.
- + New restructuring is expected to deliver $30 to $35 million of net annualized cost savings with 40 to 50 bps of incremental operating margin expansion in 2027.
- + EMEA returned to growth with Middle East revenue up 7% year-over-year aided by channel restocking.
- − Non-GAAP operating margin contracted 110 basis points year-over-year to 12.5% from 13.6%.
- − China revenue declined in the high teens, representing an estimated $4 million headwind for the remainder of the year.
- − Academic and government end markets remain below historical levels, with management wanting to see a more sustained pattern before calling it a recovery.
- − Full-year 2026 guidance was merely reaffirmed rather than raised, with currency-neutral revenue still expected to range from -3.0% to +0.5% and non-GAAP operating margin still 10.0% to 12.0%.
- − Restructuring will incur $80 to $90 million in total pre-tax charges with minimal savings expected in 2026.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BIO
this stock
Bio-Rad Laboratories, Inc.
|
$10.15B | +25.3% | +0.7% | 46.3 | 3.7% |
|
ABT
Abbott Laboratories
|
$174.90B | -19.4% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -9.3% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -20.7% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.0% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BIO | 0.0% | -1.7% | +35.0% | -1.7% | +25.3% |
| SPY | -1.2% | -0.4% | +13.1% | -0.4% | +12.1% |
| vs SPY | +1.2% | -1.3% | +22.0% | -1.3% | +13.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.